Pfizer’s 4Q17 Estimates: Products with Lower Sales

In Pfizer’s (PFE) portfolio, a few of the products reported a lower sales trend due to competition from other products in the markets. The innovative health business and essential health business include products that are losing market share.

The above chart compares revenues from few of the products with lower sales in the past few quarters.

The revenue growth will likely be impacted by lower sales of the following drugs:

• Enbrel, the blockbuster drug, is expected to report lower sales during 4Q17 due to lower sales outside the US and Canada.
• BeneFIX is expected to report lower sales during 4Q17 due to lower sales from US and international markets.
• EpiPen revenues are expected to decline in 4Q17 due to lower sales from US markets. The revenues could be partially offset by growth in EpiPen sales in international markets.
• The Prevnar family is expected to report marginally lower revenues during 4Q17. The revenue growth from international sales could be offset substantially by lower sales from US markets.
• Inlyta is expected to report lower revenues during 4Q17 due to lower sales from US and international markets.
• Zyvox’s revenues are expected to decline during 4Q17 following lower US and international sales due to patent expiry in 2015.
• Viagra’s revenues are expected to decline in 4Q17 due to lower sales in US markets. It revenues could be partially offset by increased sales from international markets.

Other drugs including Revatio, Pristiq, Precedex, Tygacil, Fragmin, the Premarin family, and Norvasc are expected to report lower revenues during 4Q17.

The First Trust NASDAQ Pharmaceuticals ETF (FTXH) holds 7.4% of its total investments in Pfizer, 7.4% in Johnson & Johnson (JNJ), 7.6% in Abbott Laboratories (ABT), and 3.9% in Allergan (AGN).